Fulcrum Therapeutics, Inc. (FULC) Institutional Ownership

Ownership Summary

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has 168 institutional investors that have filed 13F reports for the period ending December 2025.

• These investors held 109.8% of outstanding shares in December 2025, up from 86.3% in September 2025.
• They increased total shares held in Fulcrum Therapeutics by 29.11% from the prior quarter, while the number of investors in FULC increased 41.18% year over year.
• Of these 168 funds, 100 grew their exposure to Fulcrum Therapeutics, 50 cut back, and 18 maintained positions.
• In total, institutional investors held 68.72Mn shares in Fulcrum Therapeutics as of December 2025, up by 15.49Mn shares quarter on quarter, and up 15.06Mn shares year over year.
• As of December 31, 2025, SUVRETTA CAPITAL MANAGEMENT, LLC held the largest stake in Fulcrum Therapeutics with 6.56Mn shares, accounting for 10.48% of total shares outstanding.
• Top purchasers of FULC stock for the quarter ending December 2025 included VANGUARD CAPITAL MANAGEMENT LLC (2.69Mn), Jones Hill Capital LP (1.77Mn), Alyeska Investment Group, L.P. (1.33Mn), Assenagon Asset Management S.A. (1.19Mn), BlackRock, Inc. (1.13Mn).
• The biggest sellers of Fulcrum Therapeutics for the quarter ending December 2025 included ADAR1 Capital Management, LLC (2.38Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.3Mn), Nantahala Capital Management, LLC (1.24Mn), Ikarian Capital, LLC (326.31K), Point72 Asset Management, L.P. (323.38K).
• Business Quant data shows the 10 biggest positions in Fulcrum Therapeutics as of December 2025 are held by SUVRETTA CAPITAL MANAGEMENT, LLC (6.56Mn), RA CAPITAL MANAGEMENT, L.P. (6.05Mn), BlackRock, Inc. (5.39Mn), TCG Crossover Management, LLC (5.25Mn), BRAIDWELL LP (3.13Mn), Nantahala Capital Management, LLC (3.05Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.69Mn), Siren, L.L.C. (2.35Mn), First Turn Management, LLC (2.26Mn), Aberdeen Group plc (2.21Mn).